ALK: It shouldn’t be allowed to happen
Martin Barlebo, head of communications in ALK, explains how the mistake that led to the recall of 186,000 adrenaline pens was detected and how the company aims to ensure that it does not happen again.
by Stefan Singh Kailay
“It’s the kind of thing that shouldn’t be allowed to happen. But it’s also the kind of thing that does happen. That’s why there are rules for how companies like ours should handle a situation like this in regard to patient safety, which is the overriding concern in a case like this.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK given new date for crucial FDA meeting
For abonnenter
